This suggests that passive immunization with tau antibodies is really a viable therapeutic target and that the CSF volume of p-tau262/356 or from the microtubule binding domain (MTBD) can serve as a practical biomarker of tau pathology to monitor tau therapeutics in medical trials. Regardless of